Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 132 participants.

Also called NCT07089576

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07089576
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Germany, Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07089576. Non-randomized; no masking; primary purpose treatment. Start 2025-11-04 (actual); primary completion 2028-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
Acronym
ARTIZEN
Condition
Aortic Arch Aneurysm
Condition
Aortic Arch Dissection
Condition
Chronic Aortic Dissection
Condition
Acute Aortic Dissection
Intervention (Device)
Arcevo™ LSA Hybrid Stent Graft System
Lead sponsor
Artivion Inc. (class: industry)
Collaborator
Bright Research Partners (class: industry)

Record details

Record id
cardio:ct-nct07089576
Content hash
d40c93538142e8815cdb280d08f2de143b5ebda059dd86aa7bd15eb80312b3a7